McCulloch Kevin 4

What Happened
Kevin McCulloch, President and Chief Operating Officer of Xeris Biopharma (XERS), was granted equity on Jan 30, 2026: 168,463 restricted stock units (RSUs) and 225,225 stock options (derivative award), together covering 393,688 underlying shares. On Jan 31, 2026, 126,062 shares were withheld/disposed to satisfy tax withholding associated with RSU vesting; the withholding was reported at $7.36 per share, generating approximately $927,816. These grants are awards (not open-market purchases or voluntary sales).

Key Details

• Grant dates: Jan 30, 2026 (RSUs and options). Withholding: Jan 31, 2026. Filing date: Feb 2, 2026.
• Withheld/disposed shares: 68,454; 30,289; 27,319 — total 126,062 shares withheld at $7.36/share (total ≈ $927,816).
• Awards: 168,463 RSUs (F1) and 225,225 stock options (derivative, F4). RSUs/options reported as acquired at $0.00.
• Vesting: RSUs vest in equal annual installments over three years (subject to continued employment). Stock options also vest in equal annual installments over three years (F1, F4).
• Shares owned after the transaction: not specified in this filing.
• Footnotes: F2 confirms shares were withheld by the issuer to satisfy tax withholding on net-settled RSUs. F3 notes the reporting person disclaims beneficial ownership except to the extent of pecuniary interest.
• Filing timeliness: filed Feb 2, 2026; the filing date is indicated on the Form 4 and no late filing flag is provided.

Context

• This was an equity award and a net-settlement tax withholding, not an open-market sale. Withholding to cover taxes is a common administrative action when RSUs vest and does not necessarily indicate a discretionary sale by the insider.
• The stock options are subject to multi-year vesting and are not yet exercised into freely tradable shares; the RSU withholding reflects vested shares being net-settled.